After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, ...

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

Despite not differentiating itself from placebo, the Texas-based company said it plans to push pilavapadin into Phase III ...

AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

Roche’s asthma drug Xolair appears to be safer and more effective than oral immunotherapy at treating adults and children ...

The partners are building toward a regulatory submission for Tezspire in chronic rhinosinusitis with nasal polyps in the ...

The Dobbs decision has created a chilling effect on telemedicine appointments and doctors’ willingness to provide services ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...